Data as of Q4 2025 (Dec 31, 2025)

Redmile Group, LLC

โ€ขCIK: 1425738โ€ขFiling: Q4 2025

**Redmile Group, LLC** manages $1.4B across a portfolio of 34 positions, demonstrating a concentrated, technology-focused investment mandate. The fund maintains significant exposure to high-growth names, highlighted by the top holdings including SRRK at $230.0M and KRYS at $167.1M. Further substantial allocations are visible in NRIX ($153.5M) and STOK ($128.0M). This positioning suggests a deep conviction in disruptive technology sectors across its current holdings.

Total AUM
$1.4B
QoQ Performance
+32.1%
Positions
34
Top 10 Concentration
77.8%
Latest Filing
Q4 2025

Top Holdings Allocation

SRRK
KRYS
NRIX
STOK
IMNM
SRRK16.9%
KRYS12.3%
NRIX11.3%
STOK9.4%
IMNM9.0%
RGNX4.6%
ADC4.1%
COGT3.8%

๐Ÿ“ˆ Biggest Buys

NRIX
NURIX THERAPEUTICS INC
+120.0%
11.3% of portfolio
SRRK
SCHOLAR ROCK HLDG CORP
+33.7%
16.9% of portfolio
ANNX
ANNEXON INC
+59.5%
3.7% of portfolio
IMNM
IMMUNOME INC
+13.8%
9.0% of portfolio
RAPT
RAPT THERAPEUTICS INC
+60.3%
2.2% of portfolio

๐Ÿ“‰ Biggest Sells

ZYME
ZYMEWORKS INC
-86.7%
1.0% of portfolio
LIVN
LIVANOVA PLC
-87.3%
0.5% of portfolio
COGT
COGENT BIOSCIENCES INC
-34.9%
3.8% of portfolio
RGNX
REGENXBIO INC
-6.9%
4.6% of portfolio
STOK
STOKE THERAPEUTICS INC
-3.4%
9.4% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

AKRO
AKERO THERAPEUTICS INC
SOLD
$35.5M
ETNBGBP
89BIO INC
SOLD
$21.7M
KROS
KEROS THERAPEUTICS INC
SOLD
$8.7M
AM6
AMICUS THERAPEUTICS INC
SOLD
$6.1M
XERS
XERIS BIOPHARMA HOLDINGS INC
SOLD
$3.7M
+4 more exited positions

Changes from Q3 2025

NEW3 new positions
โ†‘11 increased
โ†“10 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023